SLU-PP-332 Capsules — 100 count · Research brief

Is SLU-PP-332 a Steroid? Cancer and Legal Status

Real Peptides Research TeamEditorial

Updated September 25, 20268 min read

42 WORDS

Short answer

Key takeaways

SLU-PP-332 is not a steroid: it lacks the four-ring sterane nucleus and does not act on the androgen receptor, acting instead as a pan-agonist at ERRα, ERRβ and ERRγ.
No published research demonstrates that SLU-PP-332 causes cancer, and no carcinogenicity bioassay for the compound exists in the literature.
The SLU-PP-332 cancer concern is a mechanistic inference drawn from ERRα overexpression reported in breast, ovarian and colorectal tumour research, not from any finding about the compound itself.
Because ERR activity depends on PGC-1α coactivator availability rather than ligand binding alone, effects are tissue-context dependent, which is why the SLU-PP-332 cancer question resists a simple yes or no.
SLU-PP-332 is not a controlled substance in the US but is not approved for human use and is not a lawful supplement ingredient; it is supplied for laboratory research only.
Category S0 of the WADA Prohibited List captures non-approved pharmacological substances, so SLU-PP-332 is prohibited in sport at all times whether or not it is listed by name.

No. SLU-PP-332 is not a steroid, and the reason is structural rather than semantic: it has no sterane ring system, no androgen receptor activity, and no chemical relationship to testosterone. What people are usually asking underneath that question is something else entirely. Search interest in SLU-PP-332 cancer risk outpaces interest in almost every other property of the compound, which tells you the real worry isn't classification. It's harm.

Our team supplies SLU-PP-332 as a research-use-only compound to laboratories, and two questions dominate the inbox: is SLU PP 332 a steroid, and does SLU PP 332 cause cancer. One has a clean no. The other has an honest answer that nobody enjoys hearing: the study that would settle it has never been run.

Does SLU-PP-332 cause cancer?

No published study reports that SLU-PP-332 causes cancer, and no carcinogenicity bioassay for the compound appears in the peer-reviewed literature. The SLU-PP-332 cancer question is mechanistic rather than empirical, arising from the documented role of ERRα in tumour metabolism. Published rodent experiments ran for weeks, a timescale far too short to detect tumour formation.

The oversimplification worth correcting is the idea that this debate has been settled in either direction. It hasn't. ERRα (estrogen-related receptor alpha) shows up repeatedly in oncology literature as a receptor tumours exploit for metabolic reprogramming, and most drug discovery aimed at it has chased inverse agonists rather than agonists, which is precisely why an agonist raises eyebrows. What follows covers why the steroid label is wrong, where the SLU-PP-332 cancer hypothesis actually originates, and how the compound sits under FDA, controlled-substance and anti-doping rules.

No sterane core, no androgen receptor: what the molecule actually is

SLU-PP-332 is a synthetic non-steroidal small molecule that acts as a pan-agonist at the estrogen-related receptors ERRα, ERRβ and ERRγ, a family of orphan nuclear receptors classified as NR3B1, NR3B2 and NR3B3. A steroid, by definition, is built on a cyclopentanoperhydrophenanthrene skeleton: four fused carbon rings derived biosynthetically from cholesterol. Anabolic-androgenic steroids exert their effects by binding the androgen receptor (NR3C4). SLU-PP-332 has neither the ring system nor that receptor target.

The name is what trips people up. Estrogen-related receptor sounds hormonal, and ERRs do share meaningful sequence homology with the classical estrogen receptor ERα across the DNA-binding and ligand-binding domains. They do not bind estradiol. They have no confirmed endogenous ligand at all, which is why they're called orphan receptors, and they are constitutively active, with transcriptional output governed largely by how much coactivator is present in a given tissue, chiefly PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha).

The compound was first described in peer-reviewed work from the laboratory of Thomas Burris at Saint Louis University, which is where the SLU prefix comes from. Published rodent studies report increased exercise capacity and changes in fat mass and oxidative metabolism, which is why it circulates under the exercise-mimetic label rather than an anabolic one. In our experience fielding procurement questions from metabolic research groups, the steroid framing never comes from anyone who has read the primary literature. It comes from forums. None of that, however, touches the SLU-PP-332 cancer question, which lives in a completely different body of research.

Where the cancer concern actually comes from

The SLU-PP-332 cancer concern traces back to ERRα biology, not to any finding about SLU-PP-332 itself. ERRα working with PGC-1α drives transcription of nuclear-encoded mitochondrial genes: oxidative phosphorylation subunits, fatty acid oxidation enzymes, tricarboxylic acid cycle machinery. That is the exercise-mimetic mechanism in one sentence. It is also, uncomfortably, a fair description of the metabolic flexibility aggressive tumours rely on. Published oncology research reports ERRα overexpression across breast, ovarian and colorectal tumour tissue, with studies associating higher expression with poorer prognosis, and a substantial share of ERRα drug discovery has therefore pursued inverse agonists and antagonists such as the tool compound XCT790 to switch the receptor off. SLU-PP-332 pushes the dial the other way.

Here's the nuance most write-ups skip. ERRα is not an on/off switch for tumour growth, and modelling it that way produces confident predictions that turn out wrong. Because ERR transcriptional output depends on coactivator availability rather than ligand occupancy alone, the same agonist can drive different gene programmes in two tissues with different PGC-1α levels. Parts of the literature describe context-dependent and even growth-suppressive effects of ERR modulation in specific models. That is exactly why cell-line results don't transfer cleanly, and why the SLU-PP-332 cancer question remains genuinely open rather than quietly answered.

What's missing is the boring, decisive data: no two-year rodent carcinogenicity bioassay, no published Ames genotoxicity panel, no chronic-exposure tumour-incidence study in any species. The rodent work in print ran on the order of weeks. Tumours don't surface on that timescale, so those experiments could not have detected a signal even if one existed. Anyone declaring the SLU-PP-332 cancer question resolved, in either direction, is overreading a thin record.

Approval status, scheduling, and where it lands in anti-doping

SLU-PP-332 is not approved by the FDA or any comparable regulator for any human use, and it is not a lawful dietary supplement ingredient. It is handled as a research chemical, full stop.

On scheduling: it is not a controlled substance. The Anabolic Steroid Control Act defines anabolic steroids structurally, by reference to the steroid nucleus, and SLU-PP-332 has no such nucleus, so it sits outside that definition. That is the precise reason the slu-pp-332 legal picture looks nothing like a designer steroid's. Possession and use for laboratory research is lawful; marketing it for human consumption is not, because that recharacterises it as an unapproved new drug under the Federal Food, Drug, and Cosmetic Act. Federal legislation aimed at SARM-type compounds has been introduced in Congress more than once, so verify current statutory status rather than trusting a static article.

Anti-doping is the cleanest answer of the three. The WADA Prohibited List includes category S0, Non-Approved Substances, which captures any pharmacological substance with no current approval by a governmental regulatory health authority for human therapeutic use and prohibits it at all times, in and out of competition. Metabolic modulators occupy S4. A compound does not need to be named on the WADA prohibited list to be banned, because S0 and the similar chemical structure or similar biological effects language exist to catch exactly this class of molecule. The honest slu-pp-332 danger summary is narrower than the forums suggest and worse in one specific way: acute findings in short published rodent work were unremarkable, while chronic toxicity, reproductive toxicity and the SLU-PP-332 cancer question have never been characterised at all. Nothing here is dosing, preparation or administration guidance, and Real Peptides does not provide any.

SLU-PP-332 Cancer Data Versus Steroid and SARM Risk Profiles

Putting the three classes side by side is the fastest way to see why the steroid label misleads. Note that the SLU-PP-332 column is defined by absence of data rather than by reassuring findings.

Attribute	Anabolic-androgenic steroids	SARMs (ostarine class)	SLU-PP-332	Bottom Line
Core chemistry	Four-fused-ring sterane skeleton derived from cholesterol	Non-steroidal aryl-propionamide or quinolinone scaffolds	Non-steroidal small molecule with no sterane ring at all	Only one class here is genuinely steroidal, and SLU-PP-332 is not it
Receptor target	Androgen receptor (NR3C4) full agonism	Androgen receptor with tissue-selective modulation	Pan-agonism at ERRα, ERRβ and ERRγ (NR3B1 to NR3B3), no reported AR activity	Different receptor family entirely, so androgenic side-effect reasoning does not transfer
Carcinogenicity record	Decades of animal and human data, including hepatic tumour case reports tied to 17-alpha-alkylated orals	Limited long-term data, with hepatotoxicity signals reported	No published SLU-PP-332 cancer bioassay in any species, no chronic tumour-incidence study	The SLU-PP-332 cancer question is unanswered, which is not the same as answered negatively
US regulatory status	Schedule III controlled substances under the CSA	Not scheduled, unlawful in supplements, research use only	Not scheduled, not approved for human use, research use only	Legally this tracks the SARM pattern, not the steroid pattern
Anti-doping classification	Prohibited under S1 anabolic agents	Prohibited under S1.2 other anabolic agents	Prohibited under S0 non-approved substances at all times	All three are banned in sport; only the list category differs

What If: Research Scenarios Around SLU-PP-332 Safety Questions

What if a supplier cannot produce a third-party certificate of analysis?

Treat the material as unidentified and keep it out of the study. Identity and purity are the two variables that invalidate an experiment silently, because a mislabelled or impure vial still produces clean-looking data that means nothing. A usable certificate reports the analytical method, typically HPLC for purity and mass spectrometry for identity confirmation, alongside the batch number and the compound's molecular identity. Our team has watched researchers lose an entire arm of a study to material that was never what the label claimed.

What if new carcinogenicity data is published mid-study?

Log it, re-run the risk assessment with your institutional biosafety committee, and document the decision either way. The SLU-PP-332 cancer literature is young enough that a single well-designed chronic rodent bioassay could reshape how the compound is handled overnight. Because the current record contains no long-duration tumour-incidence data, any new publication carries disproportionate weight, and retrospectively justifying a handling protocol is far harder than amending one.

What if the model involves tumour-bearing or oncogene-driven animals?

Flag the ERRα mechanism explicitly in the protocol rather than treating SLU-PP-332 as a neutral metabolic probe. Agonising a receptor that published oncology research links to tumour metabolic reprogramming is a meaningful design variable in a cancer model, not a footnote. Reviewers will ask, and the defensible position is one that names the mechanism, cites the coactivator dependence, and states the expected confound in advance.

The Blunt Truth About an Absent Carcinogenicity Record

Let's be direct about this: the SLU-PP-332 cancer question cannot be answered yes or no right now, and any source telling you otherwise is selling something. There is no two-year bioassay, no genotoxicity panel in print, and no chronic human exposure data, because there has been no approved human use at all. What exists is a plausible mechanistic worry built on ERRα's role in tumour metabolism and a handful of short rodent studies that were never designed to look for tumours. Uncharacterised is the accurate word. Safe is not.

Researchers sourcing this compound can review batch documentation on our certificates of analysis page, see specifications for SLU-PP-332, browse the wider research peptide catalog, or check supply coverage through our locations page. Every compound listed is research use only and is not for human or veterinary consumption.

The SLU-PP-332 cancer conversation gets framed as a controversy when it's really a gap, and gaps behave differently from controversies. A controversy means two bodies of evidence disagree. A gap means the experiment was never funded, never run, never published. That distinction matters because it tells you what would actually change the picture: not another forum thread or another mouse running longer on a treadmill, but one unglamorous chronic bioassay that nobody has yet paid for. Until that exists, the compound stays exactly where it is, in the laboratory, with the question written on the label.

Questions

No. SLU-PP-332 is a non-steroidal synthetic small molecule with no sterane ring system and no androgen receptor activity. It acts as a pan-agonist at the estrogen-related receptors ERRα, ERRβ and ERRγ, which are orphan nuclear receptors. The naming confusion comes from ERR homology with the estrogen receptor, not from steroid chemistry.

No published study shows that SLU-PP-332 causes cancer. No carcinogenicity bioassay for the compound exists in the peer-reviewed literature, and the published rodent work ran only weeks, far too short to detect tumour formation. The concern is a mechanistic inference from ERRα's documented role in tumour metabolism, not an observed finding.

None has been published. The SLU-PP-332 cancer record contains no two-year rodent bioassay, no chronic tumour-incidence study, and no published Ames genotoxicity panel. Available rodent experiments focused on exercise capacity and metabolic endpoints over short durations, which means carcinogenic potential has simply never been assessed in either direction.

Because ERRα drives mitochondrial and oxidative gene programmes that tumours also exploit. Published oncology research reports ERRα overexpression in breast, ovarian and colorectal tumour tissue, and much of the drug discovery aimed at ERRα has pursued inverse agonists to shut it down. SLU-PP-332 is an agonist, so the directional mismatch fuels the concern.

SLU-PP-332 is not a controlled substance in the United States and can be lawfully sold and purchased for laboratory research. It is not approved for human use and is not a lawful dietary supplement ingredient, so marketing it for human consumption would make it an unapproved new drug under the FDCA.

Functionally yes. Even where a compound is not named individually, category S0 of the WADA Prohibited List covers any pharmacological substance without current approval by a governmental health authority for human therapeutic use, prohibiting it at all times. Metabolic modulators also fall under S4. Athletes should treat SLU-PP-332 as banned.

All three are non-steroidal metabolic research compounds, but they hit different receptors. SR9009 targets REV-ERB nuclear receptors, GW501516 is a PPARδ agonist, and SLU-PP-332 is a pan-agonist at ERRα, ERRβ and ERRγ. GW501516 carries published rodent carcinogenicity findings; SLU-PP-332 has no carcinogenicity data at all.

SLU-PP-332 is supplied to qualified researchers, laboratories and institutions for in vitro and preclinical research only. It is not sold for human or veterinary consumption, and legitimate suppliers require buyers to acknowledge research-use-only terms at purchase. Institutional biosafety and chemical hygiene requirements apply at the receiving laboratory.

Pricing varies widely by purity specification, quantity and supplier, so any fixed figure would be misleading. What matters more than the headline price is what the certificate of analysis documents: HPLC purity, mass spectrometry identity confirmation, and batch traceability. Unusually cheap material almost always reflects missing or unverifiable analytical testing.

It should state the batch or lot number, the analytical methods used, purity determined by HPLC, and identity confirmed by mass spectrometry. Cross-check the molecular identity and CAS number against the compound you intend to study before procurement. A certificate without a named method or a traceable lot number is documentation in appearance only.

No. Real Peptides supplies research-use-only compounds and does not provide dosing, preparation, timing or administration guidance of any kind. Study parameters are set by the investigating laboratory and its oversight committee. What we do provide is verifiable identity and purity documentation so researchers can design experiments on known material.

The primary danger is how little is characterised. Chronic toxicity, reproductive toxicity and carcinogenicity have not been evaluated in any published study, and there is no human safety data because there has been no approved human use. Short rodent studies reported no dramatic acute findings, but that tells you nothing about long-term risk.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA